$2.01 Billion is the total value of Camber Capital Management LP's 28 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 68.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRGO | Sell | PERRIGO CO PLC | $101,136,000 | +18.6% | 2,100,000 | -4.5% | 5.04% | +24.6% |
| GBT | Sell | GLOBAL BLOOD THERAPEUTICS INC | $95,274,000 | +3.2% | 1,800,000 | -20.0% | 4.75% | +8.3% |
| UHS | Sell | UNIVERSAL HLTH SVCS INCcl b | $86,951,000 | -17.1% | 650,000 | -27.8% | 4.33% | -13.0% |
| THC | Sell | TENET HEALTHCARE CORP | $50,470,000 | -9.4% | 1,750,000 | -46.2% | 2.52% | -4.8% |
| CLVS | Sell | CLOVIS ONCOLOGY INC | $37,230,000 | -26.0% | 1,500,000 | -46.4% | 1.86% | -22.3% |
| ELGX | Sell | ENDOLOGIX INC | $6,147,000 | -7.7% | 930,001 | -90.0% | 0.31% | -3.2% |
| BHC | Exit | BAUSCH HEALTH COS INC | $0 | – | -1,000,000 | -100.0% | -0.88% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.92% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INC | $0 | – | -1,300,000 | -100.0% | -1.26% | – |
| MYL | Exit | MYLAN N Vcall | $0 | – | -1,000,000 | -100.0% | -1.30% | – |
| HCA | Exit | HCA HEALTHCARE INC | $0 | – | -250,000 | -100.0% | -1.48% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -600,000 | -100.0% | -2.08% | – |
| CAH | Exit | CARDINAL HEALTH INCcall | $0 | – | -1,000,000 | -100.0% | -2.12% | – |
| BMY | Exit | BRISTOL MYERS SQUIBB COcall | $0 | – | -1,000,000 | -100.0% | -2.47% | – |
| GSK | Exit | GLAXOSMITHKLINE PLCsponsored adr | $0 | – | -2,000,000 | -100.0% | -3.62% | – |
| CELG | Exit | CELGENE CORP | $0 | – | -1,500,000 | -100.0% | -4.56% | – |
| MCK | Exit | MCKESSON CORP | $0 | – | -875,000 | -100.0% | -4.59% | – |
| AGN | Exit | ALLERGAN PLCcall | $0 | – | -1,000,000 | -100.0% | -6.34% | – |
| TSRO | Exit | TESARO INC | $0 | – | -2,800,000 | -100.0% | -9.86% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.